The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Frederico Gomes - ATB Capital Markets - Analyst
: Congrats on the great quarter. First question on the revenue growth that you saw in the global medical cannabis sales. So we know those sales are
sometimes, I guess, quite volatile because of the timing of some of those shipments, et cetera.
So would you say that the sales level is sort of representative of what you will be doing going forward? And in terms -- what visibility do you have
on that? And is the growth sustainable from these levels?
Question: Frederico Gomes - ATB Capital Markets - Analyst
: Perfect. Second question, I'm curious about your RAC business in Canada. It's obviously much smaller than the medical platform. And I guess most
of your profits are coming from medical. So how do you think about that RAC platform? Do you see any chances of growing that? Does it make
sense to keep it given that you're medically focused right now. So how should we think about recreational going forward?
Question: Frederico Gomes - ATB Capital Markets - Analyst
: And if I can ask just one more question here. About capital allocation, you're now close to your free cash flow goal, I guess, for next quarter, and
you have lots of cash on the balance sheet, debt free. So how do you plan to allocate that capital?
And is M&A something that you would be more, I guess, actively considering now that you are free cash flow positive? Do you plan to invest
organically in the business, just capital allocation options and how are you looking at them?
Question: Pablo Zuanic - Zuanic & Associates - Analyst
: Miguel, I have a few questions, but first, can I start by asking you your impressions following the results of the US election. How does that impact
Aurora, if in any way? And what would you say to those cannabis investors that were so vested in Florida going RAC or the reform process in the
US that are so focused on MSO stocks, what would you say from your perspective?
Question: Pablo Zuanic - Zuanic & Associates - Analyst
: Look, and just moving on to -- just comparing your Australian and German operation. I mean, obviously, from the acquisitions you made in Australia,
you have more control of the overall business, and that's leading to growth apparently based on what you described.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 06, 2024 / 1:00PM, ACB.TO - Q2 2025 Aurora Cannabis Inc Earnings Call
Is that an opportunity in Germany or you're pretty much fully integrated there, at least from a sales and distribution perspective there. I'm just
trying to understand, even in Poland, if there's room to do what you did in Australia to do in Germany and Poland or you were already there?
Question: Pablo Zuanic - Zuanic & Associates - Analyst
: Okay. And one last one, if I can. We're starting to hear about some cities in Germany doing these pilot programs, I guess, for the Quasi reg program.
Could we have that an impact on medical sales or the way the medical market develops in Germany.
And I guess part B of that question, just remind us in terms of what do you see as underlying growth in the German market right now and whether
you are running at a rate or slightly below or slightly above?
|
